BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34162140)

  • 21. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
    Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
    Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.
    Li J; Zhou C; Dong B; Zhong H; Chen S; Li Q; Wang Z
    Cancer Biol Ther; 2016 Dec; 17(12):1231-1239. PubMed ID: 27645568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
    Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
    Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
    Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
    Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
    Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing.
    Mota G; Moldovan I; Calugaru A; Hirt M; Kozma E; Galatiuc C; Brasoveanu L; Boltz-Nitulescu G
    Scand J Immunol; 2004 Mar; 59(3):278-84. PubMed ID: 15030579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens.
    Kumar S; Nayak B; Collins PL; Samal SK
    J Virol; 2011 Jul; 85(13):6521-34. PubMed ID: 21525340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity.
    Mandelboim O; Malik P; Davis DM; Jo CH; Boyson JE; Strominger JL
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5640-4. PubMed ID: 10318937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
    van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
    Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
    Heiskala M; Ståhls A; Seppälä I; Timonen T
    Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.
    Vallera DA; Zhang B; Gleason MK; Oh S; Weiner LM; Kaufman DS; McCullar V; Miller JS; Verneris MR
    Cancer Biother Radiopharm; 2013 May; 28(4):274-82. PubMed ID: 23611188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
    Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
    MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a potential neutralizing linear epitope of hemagglutinin-neuraminidase in Newcastle disease virus.
    Jin Z; Wei Q; Bi Y; Li Y; Huo N; Mou S; Wang W; Liu H; Yang Z; Chen H; Xiao S
    Virol J; 2021 Jan; 18(1):8. PubMed ID: 33407693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
    Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
    Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant-attenuated
    Ding K; Shang K; Yu ZH; Yu C; Jia YY; He L; Liao CS; Li J; Zhang CJ; Li YJ; Wu TC; Cheng XC
    J Vet Sci; 2018 Mar; 19(2):232-241. PubMed ID: 29032660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc gamma-receptor III (CD 16) is involved in NK-B cell interaction.
    Lenz P; Gessner JE; Sautes C; Schmidt RE
    Immunobiology; 1996; 196(4):387-98. PubMed ID: 9061379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newcastle disease virus (NDV) vaccine based on immunization with avian cells expressing the NDV hemagglutinin-neuraminidase glycoprotein.
    Cosset FL; Bouquet JF; Drynda A; Chebloune Y; Rey-Senelonge A; Kohen G; Nigon VM; Desmettre P; Verdier G
    Virology; 1991 Dec; 185(2):862-6. PubMed ID: 1660204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.